Kyverna Therapeutics shares fall 1.26% in premarket as KYV-101 shows progress in autoimmune disease trials.

Kyverna Therapeutics, Inc. fell 1.26% in premarket trading, as its lead drug candidate KYV-101 progresses in clinical development for autoimmune diseases, particularly in neuroinflammation and rheumatology. Despite a net loss of $44.64 million in the first quarter of fiscal 2025, market attention remains on its future potential. H.C. Wainwright maintains a hold rating and a $4 target price for the company.